Royal Victoria Hospital, UK.
Southampton University Hospitals NHS Trust, UK.
Ann R Coll Surg Engl. 2021 Jul;103(7):508-513. doi: 10.1308/rcsann.2021.0026. Epub 2021 Apr 29.
Autologous stem cell progenitor implantation into necrotic lesions of the femoral head has previously been described as a potential treatment for avascular necrosis (AVN), on the basis that there is a reduced number of functioning stem cells in the marrow within the necrotic segment. We present a case series of patients with AVN that underwent core decompression with autologous stem cell implantation using a new device.
The records and imaging of patients with AVN of the femoral head treated by a single surgeon were retrospectively reviewed. All patients were treated with core decompression and stem cell progenitor implantation, using the PerFuse system. Preoperatively, demographic information, AVN staging (as per Ficat and Arlet classification) and visual analogue pain scores (VAS) of the hips were recorded. These results were compared with postoperative VAS and imaging, with further review on the progression of AVN.
We treated 14 hips in 13 patients with an average follow up of 12 months. Patients with Ficat I-II were selected for the procedure. The average preoperative VAS was 3.9. Postoperatively, this dropped to 2.6, with over half of patients reporting at least a two-point decrease in pain. Eight of the 14 treated hips showed no radiological progression of the disease, while six showed femoral head collapse requiring total hip arthroplasty (THA) at an average of ten months after treatment.
Our early findings indicate that hip decompression with stem cell progenitor implantation for AVN of the femoral head provides symptomatic relief and may be beneficial in arresting progression of disease using this simple new device.
自体干细胞祖细胞植入股骨头坏死病灶被认为是治疗股骨头缺血性坏死(AVN)的一种潜在方法,因为坏死节段骨髓中的功能干细胞数量减少。我们报告了一组采用新设备行自体干细胞植入的核心减压治疗 AVN 患者的病例系列。
回顾性分析了一位外科医生治疗的 AVN 患者的记录和影像学资料。所有患者均采用 PerFuse 系统行核心减压和干细胞祖细胞植入治疗。术前记录患者的人口统计学信息、AVN 分期(Ficat 和 Arlet 分类)和髋关节视觉模拟疼痛评分(VAS)。将这些结果与术后 VAS 和影像学结果进行比较,并进一步观察 AVN 的进展情况。
我们治疗了 13 例患者的 14 髋,平均随访 12 个月。选择 Ficat I-II 期的患者进行该手术。术前平均 VAS 为 3.9。术后降至 2.6,超过一半的患者报告疼痛至少减轻了 2 分。14 例治疗髋关节中,8 例无疾病进展,6 例出现股骨头塌陷,在治疗后平均 10 个月需要全髋关节置换术(THA)。
我们的早期发现表明,股骨头缺血性坏死的髋关节减压联合干细胞祖细胞植入可缓解症状,并可能通过这种简单的新设备阻止疾病进展。